Foster & Motley Inc. Has $861,000 Stake in Eli Lilly and Company (NYSE:LLY)

Foster & Motley Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 972 shares of the company’s stock after selling 150 shares during the quarter. Foster & Motley Inc.’s holdings in Eli Lilly and Company were worth $861,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares during the period. Quent Capital LLC increased its stake in shares of Eli Lilly and Company by 5.3% in the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after buying an additional 249 shares during the period. Empowered Funds LLC increased its stake in shares of Eli Lilly and Company by 8.3% in the first quarter. Empowered Funds LLC now owns 32,027 shares of the company’s stock valued at $24,916,000 after buying an additional 2,452 shares during the period. Guardian Asset Advisors LLC increased its stake in shares of Eli Lilly and Company by 2.7% in the first quarter. Guardian Asset Advisors LLC now owns 3,415 shares of the company’s stock valued at $2,657,000 after buying an additional 91 shares during the period. Finally, Prospera Private Wealth LLC acquired a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $260,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $797.58 on Friday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The business’s fifty day moving average is $901.75 and its 200 day moving average is $867.32. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market cap of $757.16 billion, a P/E ratio of 86.22, a P/E/G ratio of 3.05 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the business earned $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays reduced their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.